Alerts will be sent to your verified email
Verify EmailVENUSREM
|
Venus Remedies
|
Beta Drugs
|
Lincoln Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
8.87 % | 22.74 % | 15.1 % |
|
5yr average Equity Multiplier
|
1.32 | 1.82 | 1.26 |
|
5yr Average Asset Turnover Ratio
|
0.96 | 1.03 | 0.82 |
|
5yr Avg Net Profit Margin
|
6.91 % | 12.23 % | 14.59 % |
|
Price to Book
|
2.46 | 6.53 | 2.12 |
|
P/E
|
15.89 | 38.54 | 17.29 |
|
5yr Avg Cash Conversion Cycle
|
46.96 Days | 7.75 Days | -6.41 Days |
|
Inventory Days
|
75.64 Days | 46.07 Days | 43.91 Days |
|
Days Receivable
|
54.28 Days | 91.57 Days | 91.75 Days |
|
Days Payable
|
58.86 Days | 119.03 Days | 128.38 Days |
|
5yr Average Interest Coverage Ratio
|
396.11 | 14.42 | 63.13 |
|
5yr Avg ROCE
|
8.42 % | 27.84 % | 19.81 % |
|
5yr Avg Operating Profit Margin
|
10.14 % | 21.76 % | 18.35 % |
|
5 yr average Debt to Equity
|
0.08 | 0.29 | 0.0 |
|
5yr CAGR Net Profit
|
-6.01 % | 29.34 % | 5.76 % |
|
5yr Average Return on Assets
|
6.69 % | 12.69 % | 11.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
41.76 % | 64.63 % | 49.78 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -2.1 % | 2.78 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Venus Remedies
|
Beta Drugs
|
Lincoln Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|